Inositol phosphate
The phosphate storage form of inositol found naturally in seeds, grains, and legumes. Has real preclinical anticancer activity and inhibits calcium-oxalate crystallization (relevant to kidney stones). Human evidence is preliminary — one small pilot trial in breast cancer chemotherapy patients showed quality-of-life benefit. Chelates dietary minerals, which is both a use case (kidney stones) and a caution (iron/zinc deficiency risk).
Quick decision guide
May help most
Adults interested in a low-risk adjunct during cancer chemotherapy (under oncology supervision), or as a calcium-oxalate kidney-stone prevention adjunct.
Common dosing range
Supplement dose: 800–4,800 mg/day. Dietary intake from a high-fiber plant-based diet: 1–6 g/day.
When to expect effects
Weeks to months for any clinical-endpoint effect.
Watch out for
Chelates iron, zinc, calcium, and magnesium — take separately from mineral supplements (≥2 hours apart). Iron-deficient adults should avoid high-dose IP6.
Evidence snapshot
What is it
Inositol phosphates are inositol molecules with one or more phosphate groups attached. The class includes inositol monophosphate (IP1) through inositol hexaphosphate (IP6, also called phytic acid or phytate). They occur naturally in plants (especially seeds) and play essential intracellular signaling roles in animals.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Cancer prevention / adjunctive therapy Limited Evidence | Strong in vitro and animal anticancer activity; one small pilot RCT in breast cancer shows preserved blood counts and QoL during chemo | Cancer patients receiving chemotherapy who want a low-risk adjunct, under oncology supervision | Weeks (during chemotherapy cycles) |
Calcium oxalate kidney stone prevention Limited Evidence | Inhibits calcium oxalate crystallization in vitro and in animals; human urinary endpoint evidence is mixed | Recurrent calcium oxalate stone formers as an adjunct to hydration, citrate, and dietary changes | Months for stone-recurrence outcomes (if it works at all) |
Antioxidant / mineral-chelation (mechanism) Limited Evidence | Demonstrated chelation of iron, zinc, calcium, magnesium in vitro and in vivo | People with iron-overload conditions (hemochromatosis) where iron chelation might theoretically help — but specific clinical protocols don't use IP6 | Acute (each dose chelates immediately in the gut) |
Cancer prevention / adjunctive therapy
- Effect
- Strong in vitro and animal anticancer activity; one small pilot RCT in breast cancer shows preserved blood counts and QoL during chemo
- Best fit
- Cancer patients receiving chemotherapy who want a low-risk adjunct, under oncology supervision
- Time
- Weeks (during chemotherapy cycles)
Calcium oxalate kidney stone prevention
- Effect
- Inhibits calcium oxalate crystallization in vitro and in animals; human urinary endpoint evidence is mixed
- Best fit
- Recurrent calcium oxalate stone formers as an adjunct to hydration, citrate, and dietary changes
- Time
- Months for stone-recurrence outcomes (if it works at all)
Antioxidant / mineral-chelation (mechanism)
- Effect
- Demonstrated chelation of iron, zinc, calcium, magnesium in vitro and in vivo
- Best fit
- People with iron-overload conditions (hemochromatosis) where iron chelation might theoretically help — but specific clinical protocols don't use IP6
- Time
- Acute (each dose chelates immediately in the gut)
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Cancer prevention / adjunctive therapy
Disease adjunctIP6 has substantial preclinical evidence: it inhibits proliferation of breast, colon, prostate, and other cancer cell lines in vitro, and slows tumor growth in animal models. The Vucenik & Shamsuddin 2003 review summarized the mechanism (PKC-delta-dependent p27Kip1 increase, retinoblastoma protein hypophosphorylation, anti-angiogenic effects). Human evidence remains limited. The Bacic 2010 pilot RCT in 14 breast cancer patients on chemotherapy found IP6 + inositol preserved leukocyte and platelet counts and improved quality of life vs placebo — promising but too small to be definitive. MSKCC's About Herbs notes the chemotherapy supportive-care signal but emphasizes the need for larger trials.
Bottom line: Promising preclinical mechanism + one tiny human trial = reasonable to discuss with your oncologist, not strong evidence on its own.
Evidence is mixed
Preclinical evidence is substantial; human evidence is limited to one small pilot trial. Don't extrapolate cell-line and animal data to firm clinical recommendations.
Calcium oxalate kidney stone prevention
Biomarker supportGrases & Costa-Bauzá and colleagues showed phytate (IP6) inhibits calcium oxalate crystallization in biological fluids both in vitro and in vivo. Epidemiological studies have linked higher dietary phytate intake (from whole grains and legumes) to lower kidney stone risk. However, a more recent human study in South African populations found that adding dietary IP6 did not change urinary risk factors for stone formation, raising questions about whether dietary IP6 actually reaches the urine in sufficient quantity. As a supplement adjunct alongside hydration and citrate, it's plausible but not proven.
Bottom line: Mechanism is real; clinical proof of stone-reduction in humans is weak. Reasonable adjunct if it doesn't interfere with your other mineral status.
Antioxidant / mineral-chelation (mechanism)
Mechanism onlyIP6 chelates iron and other transition metals, reducing the formation of hydroxyl radicals from the Fenton reaction. This is the basis for its in vitro antioxidant activity. As with all 'mechanism only' claims, it doesn't automatically translate to clinical benefit — and the same chelation that reduces hydroxyl-radical formation also reduces iron and zinc absorption in the gut. Useful framing context, not a stand-alone reason to supplement.
Bottom line: Mineral-chelating mechanism is genuine and is why dietary phytate matters for iron and zinc nutrition — but using IP6 as a 'systemic antioxidant' is a stretch.
How it works
How to take it
What to track
Bottom line: Take between meals, watch your mineral status, and reset expectations: the evidence is mostly preclinical and the strongest human signal is a pilot study in 14 patients.
4 commercial forms
Compare the main delivery options and what they’re best suited for.
IP6 supplement (capsule or powder)
Standard formInositol hexaphosphate as a capsule or powder, typically 800–4,800 mg/day. The form used in the small Bacic 2010 chemotherapy pilot trial when combined with free inositol. Convenient for dose-control.
Some debate about systemic absorption of intact IP6; partial hydrolysis to lower phosphates in the gut occurs.
IP6 + Inositol combination
Trial-tested comboThe pairing studied in the breast cancer pilot trial (Bacic 2010). Ratios vary by manufacturer; the trial product used a proprietary blend.
Free inositol is well absorbed; IP6 partial.
Dietary phytate from whole foods
Where most people meet itWhole grains (oats, brown rice, wheat bran), legumes (beans, lentils, chickpeas), nuts and seeds (almonds, sesame, pumpkin), and soy foods are rich in IP6. A whole-food plant-rich diet provides 1–6 g/day. This is the most-studied dietary context for IP6's effects.
Food preparation (soaking, sprouting, fermenting, leavening) reduces phytate content if iron/zinc are concerns.
Phytase-enzyme-treated foods
Phytate-reducedSourdough bread and properly soaked/sprouted legumes have lower phytate due to phytase enzyme activity during fermentation. Useful for iron-deficient populations who still want to eat whole-grain foods.
Reduces phytate by 50–90% depending on technique; improves iron/zinc bioavailability.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Worsens iron and zinc deficiency through mineral chelation — significant for iron-deficient populations, vegans, and menstruating women already at risk for low iron.
Antiplatelet activity in vitro — may increase bleeding risk when combined with anticoagulants or antiplatelet drugs.
Who should avoid it
- People with iron deficiency or iron-deficiency anemia.
- People with zinc deficiency or marginal zinc intake (especially vegans and adults on restricted diets).
- People taking anticoagulants (warfarin, DOACs) or antiplatelets (aspirin, clopidogrel) without clinician oversight.
- Pregnant or breastfeeding women — minimize phytate intake to support iron and zinc adequacy.
- Children with growth or nutritional concerns — chronic high phytate intake can impair iron and zinc nutrition.
Pregnancy & breastfeeding
Pregnancy and lactation are not contexts for high-dose IP6 supplementation. Iron and zinc requirements rise during pregnancy, and IP6 chelation works against this. Dietary intake from a balanced diet (including some grains and legumes) is fine.
Bottom line: Generally safe at supplement doses for short-term use in well-nourished adults; main caution is mineral chelation. Avoid in iron/zinc deficiency, pregnancy, and on serious anticoagulants.
Interactions
IP6 strongly chelates non-heme iron, reducing absorption. Take iron supplements at least 2 hours away from IP6.
Same chelation mechanism as iron. Take zinc and IP6 at least 2 hours apart.
IP6 binds calcium. Space dosing by 2 hours. (Note: this same mechanism is the basis for the kidney-stone-prevention hypothesis.)
IP6 has antiplatelet activity in vitro and may add to bleeding risk. Discuss with prescriber before combining.
Chelation reduces magnesium absorption modestly. Space dosing.
Food sources
| Food | Amount | %DV |
|---|---|---|
| Wheat bran | 100 g (~3000-5000 mg phytate) | — |
| Brazil nuts | 100 g (~1700-6300 mg) | — |
| Almonds | 100 g (~1400-3200 mg) | — |
| Sesame seeds | 100 g (~1400-5400 mg) | — |
| Oats, whole | 100 g (~500-1200 mg) | — |
| Brown rice | 100 g cooked (~110-220 mg) | — |
| Lentils, cooked | 100 g (~100-300 mg) | — |
| Beans (kidney, black), cooked | 100 g (~150-280 mg) | — |
| Tofu / soybeans | 100 g (~750-1450 mg) | — |
Wheat bran
- Amount
- 100 g (~3000-5000 mg phytate)
- %DV
- —
Brazil nuts
- Amount
- 100 g (~1700-6300 mg)
- %DV
- —
Almonds
- Amount
- 100 g (~1400-3200 mg)
- %DV
- —
Sesame seeds
- Amount
- 100 g (~1400-5400 mg)
- %DV
- —
Oats, whole
- Amount
- 100 g (~500-1200 mg)
- %DV
- —
Brown rice
- Amount
- 100 g cooked (~110-220 mg)
- %DV
- —
Lentils, cooked
- Amount
- 100 g (~100-300 mg)
- %DV
- —
Beans (kidney, black), cooked
- Amount
- 100 g (~150-280 mg)
- %DV
- —
Tofu / soybeans
- Amount
- 100 g (~750-1450 mg)
- %DV
- —
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Does IP6 block mineral absorption?⌄
Yes. It can reduce absorption of iron, zinc, and calcium when consumed in the same meal. Time it apart from mineral-rich foods if absorption matters to you.
References by claim
Cancer prevention / adjunctive therapy
Calcium oxalate kidney stone prevention
Grases & Costa-Bauzá, 1999 — Anticancer Research (1999) link
Track Inositol phosphate with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.